NASDAQ · AEMD
Healthcare · Medical - Devices
$6.81
Up+$0.24 (+3.65%)
Updated Sep 24, 2026, 10:37 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AEMD closed at $6.81 after 20 trading sessions, up 198.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 23, 2026 | $6.56 | $6.94 | $6.31 | $6.81 | 301.96K |
| Sep 22, 2026 | $6.20 | $7.2127 | $6.20 | $6.57 | 764.6K |
| Sep 21, 2026 | $6.89 | $6.9263 | $6.03 | $6.32 | 761.85K |
| Sep 18, 2026 | $6.38 | $6.56 | $5.80 | $6.31 | 2.51M |
| Sep 17, 2026 | $8.48 | $9.50 | $6.01 | $6.78 | 92.6M |
| Sep 16, 2026 | $1.46 | $1.50 | $1.41 | $1.43 | 43.65K |
| Sep 15, 2026 | $1.46 | $1.56 | $1.46 | $1.47 | 47.43K |
| Sep 14, 2026 | $1.48 | $1.5675 | $1.45 | $1.54 | 56.97K |
| Sep 11, 2026 | $1.57 | $1.60 | $1.52 | $1.53 | 103.64K |
| Sep 10, 2026 | $1.67 | $1.69 | $1.55 | $1.56 | 156.9K |
| Sep 9, 2026 | $1.77 | $1.77 | $1.69 | $1.69 | 89.96K |
| Sep 8, 2026 | $1.79 | $1.8641 | $1.74 | $1.81 | 55.8K |
| Sep 4, 2026 | $1.79 | $1.82 | $1.70 | $1.82 | 165.47K |
| Sep 3, 2026 | $1.79 | $2.06 | $1.67 | $1.93 | 683.48K |
| Sep 2, 2026 | $1.71 | $1.8881 | $1.71 | $1.82 | 234.49K |
| Sep 1, 2026 | $1.90 | $2.00 | $1.81 | $1.84 | 295.97K |
| Aug 31, 2026 | $2.29 | $2.32 | $1.92 | $2.06 | 849.65K |
| Aug 28, 2026 | $2.92 | $3.29 | $2.44 | $2.49 | 45.12M |
| Aug 27, 2026 | $2.24 | $2.35 | $2.17 | $2.17 | 16.55M |
| Aug 26, 2026 | $2.44 | $2.445 | $2.2201 | $2.28 | 28.89K |
The latest Smart Investors Daily articles mentioning AEMD.
AEMD research
Company profile and research snapshot.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 10, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 19, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
Aethlon Medical (NASDAQ:AEMD) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Benzinga · Sep 17, 2026
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Benzinga · Sep 17, 2026
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares
Yahoo · Sep 17, 2026
Aethlon Medical (NASDAQ:AEMD) shares surged more than 400% in pre-market trading on Thursday after the company announced a definitive merger agreement with privately held biotechnology company North Immunology. The all-stock transaction will combine the businesses through Aethlon’s wholly owned subsidiaries, Nighthawk Merger Sub Corp.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AEMD.
